Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia

av Lavrov, Alexander V., Chelysheva, Ekaterina Y., Smirnikhina, Svetlana A., Shukhov, Oleg A., Turkina, Anna G., Adilgereeva, Elmira P., Kutsev, Sergey I.
I publikationen BMC Genet (2016)

Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia

av Lavrov, Alexander V., Ustaeva, Oksana A., Adilgereeva, Elmira P., Smirnikhina, Svetlana A., Chelysheva, Ekaterina Y., Shukhov, Oleg A., Shatokhin, Yuriy V., Mordanov, Sergey V., Turkina, Anna G., Kutsev, Sergey I.
I publikationen PLoS One (2017)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

av Gambacorti‐Passerini, Carlo, Kantarjian, Hagop M., Kim, Dong‐Wook, Khoury, Hanna J., Turkina, Anna G., Brümmendorf, Tim H., Matczak, Ewa, Bardy‐Bouxin, Nathalie, Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Cortes, Jorge E.
I publikationen Am J Hematol (2015)

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

av Lavrov, Alexander V., Chelysheva, Ekaterina Yu., Adilgereeva, Elmira P., Shukhov, Oleg A., Smirnikhina, Svetlana A., Kochergin-Nikitsky, Konstantin S., Yakushina, Valentina D., Tsaur, Grigory A., Mordanov, Sergey V., Turkina, Anna G., Kutsev, Sergey I.
I publikationen BMC Med Genomics (2019)

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

av Cortes, Jorge E., Kantarjian, Hagop M., Brümmendorf, Tim H., Kim, Dong-Wook, Turkina, Anna G., Shen, Zhi-Xiang, Pasquini, Ricardo, Khoury, H. Jean, Arkin, Steven, Volkert, Angela, Besson, Nadine, Abbas, Richat, Wang, Junyuan, Leip, Eric, Gambacorti-Passerini, Carlo
I publikationen Blood (2011)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

av Hughes, Timothy P., Munhoz, Eduardo, Aurelio Salvino, Marco, Ong, Tee Chuan, Elhaddad, Alaa, Shortt, Jake, Quach, Hang, Pavlovsky, Carolina, Louw, Vernon J., Shih, Lee‐Yung, Turkina, Anna G., Meillon, Luis, Jin, Yu, Acharya, Sandip, Dalal, Darshan, Lipton, Jeffrey H.
I publikationen Br J Haematol (2017)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

av Gambacorti-Passerini, Carlo, Brümmendorf, Tim H, Kim, Dong-Wook, Turkina, Anna G, Masszi, Tamas, Assouline, Sarit, Durrant, Simon, Kantarjian, Hagop M, Khoury, H Jean, Zaritskey, Andrey, Shen, Zhi-Xiang, Jin, Jie, Vellenga, Edo, Pasquini, Ricardo, Mathews, Vikram, Cervantes, Francisco, Besson, Nadine, Turnbull, Kathleen, Leip, Eric, Kelly, Virginia, Cortes, Jorge E
Publicerad 2014